Title
Unlocking the Potential of TROP2-, HER2-, and HER3-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches

Program Description
Educating clinicians on the novel therapeutic role of TROP2, HER2, and HER3 is necessary to achieve an improved clinician understanding of the growing complexity of NSCLC management. This initiative aims to improve clinicians’ knowledge of emerging TROP2, HER2, and HER3 data and to enhance their proficiency in utilizing this data in clinical practice. Therefore, the proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

Intended Audiences
Community medical oncology team members (MD/DO, APPs, clinical pharmacists)

Commercial Supporters
This activity is supported by an educational grant from AstraZeneca and Daiichi Sankyo.

Educational Objectives
After taking part in this educational activity, clinicians should become better able to:

• Enhance efficacy and patient response to combination treatment with emerging TROP2-directed ADCs in the first- and second-line treatment of patients with advanced/metastatic NSCLC 
• Identify, mitigate, and manage adverse events associated with TROP2-directed therapies by monitoring both treatment response and patient quality of life 
• Distinguish the clinical significance of HER2-related genomic alterations while selecting the optimal testing methodology for broad application in all patients with mNSCLC 
• Integrate comprehensive and longitudinal treatment strategies that optimize dosing, pulmonary/cardiac safety, and distant metastases for patients receiving HER2-directed therapies in NSCLC 
• Describe the biologic and clinical rationale for targeting HER3 and use of HER3-directed ADCs in NSCLC management 
• Evaluate clinical evidence for HER3-directed ADCs in patients who progress following TKIs or platinum-based chemotherapy in EGFR-mutant NSCLC 
• Integrate efficacy and safety data on HER3-directed agents and/or combinations into sequencing considerations for patients with progressive stage NSCLC 

Accredited Provider & Accreditation Statements

Accredited by Global Learning Collaborative

In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and RealCME. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement
Global Learning Collaborative (GLC) designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for 5.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Course Faculty and Disclosures

	Benjamin Levy, MD Associate Professor Johns Hopkins Sidney Kimmel Cancer Center Washington, DC Consulting Fees: AstraZeneca, DSI, Janssen
	Alexander Spira, MD, PhD, FACP Medical Oncologist Director of VCS Research Institute Director of VCS Phase 1 Program Medical Director, US Oncology Lung Program Fairfax, VA Ownership Interests: Lilly Consulting Fees: Amgen, Black Diamond Therapeutics, Gritstone Bio, Incyte, Janssen Research & Development, Jazz Pharmaceuticals, Lilly, Mersana, Mirati Therapeutics, Novartis, Regeneron, Sanofi, Takeda Research: Astellas Pharma, AstraZeneca, Boehringer Ingelheim, LAM Therapeutics, MedImmune, Novartis, Regeneron, Roche
	Helena Yu, MD Associate Attending Memorial Sloan Kettering Cancer Center New York, NY Consulting Fees: Abbvie, AstraZeneca, Black Diamond, Blueprint, C4 Therapeutics, Cullinan, Daiichi Sankyo, Janssen, Ipsen, Takeda Research: AstraZeneca, Black Diamond, Blueprint, Cullinan, Daiichi Sankyo, ERASCA, Janssen, Novartis, Pfizer
	Pasi Janne, MD Senior Vice President for Translational Medicine Dana-Farber Cancer Institute Boston, MA Consulting Fees: Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Blueprint Medicines, Chugai Pharmaceuticals, Daiichi Sankyo, Duality Biologics, Eli Lilly, Esai, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi Pharmaceuticals, Scorpion Therapeutics, SFJ Pharmarceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta,Voronoi Research: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA, Revolution Medicines, Takeda Oncology Patents, Royalties, Other Intellectual Property: LabCorp
	Jyoti Patel, MD Professor of Medicine Northwestern University Chicago, IL Consulting Fees: AbbVie, AstraZeneca, Eli Lilly, Genentech, Takeda

Disclosure of Financial Relationships Policy
Global Learning Collaborative adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this interprofessional continuing education (IPCE) activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of GLC, Prova Education, and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact info@provaeducation.com

Accredited Provider Disclosure 
None of the planners, reviewers, or Global Learning Collaborative staff for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

Method of Participation/Instructions
This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline Assessment - 0.50 credit
• Final Assessment - 0.50 credit 
• Self-Study Module 1 - 0.25 credit
• Self-Study Module 2 - 0.25 credit
• Self-Study Module 3 - 0.50 credit
• Group Challenge 1 - 0.50 credit
• Group Challenge 2 - 0.50 credit
• Group Challenge 3 - 0.50 credit
• Live Group Discussion 1 - 0.75 credit
• Live Group Discussion 2 - 0.75 credit